Entia Biosciences (OTC: ERGO) develops patented, pharmaceutical-grade organic compounds, including one known as ErgoD2. Entia believes that ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. Entia’s goal is to clinically validate and commercialize ErgoD2 through the prescription medical food and OTC supplement channels. Entia also develops and markets health-related cosmeceuticals. For more information, visit the company’s website at www.entiabio.com.